Begley C M
Midwifery. 1990 Jun;6(2):60-72. doi: 10.1016/s0266-6138(05)80150-0.
A randomised, controlled trial of 1429 women was carried out to compare 'active' management of the third stage of labour, using i.v. Ergometrine 0.5 mgs, with a method of 'physiological' management, in women at 'low risk' to haemorrhage. A separate sub-study, with 168 women in each of the two groups, examined the possible effects of Ergometrine on serum prolactin levels and the duration of breast feeding. No difference was found in peak (post-suckling) serum prolactin levels taken from 126 women between 48 and 72 hours postnatal. Further studies with larger sample sizes would give a more dependable result. Women who did not receive the drug Ergometrine were more likely to continue breast feeding for longer than four weeks than those who did (p less than 0.05). It is recommended that this drug should not be given routinely to women intending to breast feed.
对1429名女性进行了一项随机对照试验，以比较在出血“低风险”女性中，使用静脉注射0.5毫克麦角新碱对第三产程进行“积极”管理与“生理性”管理方法的效果。一项单独的子研究中，两组各有168名女性，研究了麦角新碱对血清催乳素水平和母乳喂养持续时间的可能影响。对126名产后48至72小时的女性进行检测，发现其高峰（哺乳后）血清催乳素水平并无差异。样本量更大的进一步研究将得出更可靠的结果。未接受麦角新碱药物治疗的女性比接受该药物治疗的女性更有可能持续母乳喂养超过四周（p小于0.05）。建议不要对打算母乳喂养的女性常规使用此药。
